Basic Principles
The Company always pursues and continually works to enhance the best corporate governance practices in line with the following basic principles:
- The Company will strive to effectively secure the rights of shareholders and will ensure shareholder equality.
- The Company will strive to cooperate fully with stakeholders and will foster a corporate culture and climate that respects the ethics of sound business practices.
- The Company will provide full disclosure of the Company's financial, management, and other information to ensure transparency.
- The Board of Directors will establish an environment where bold management decisions are made based on corporate strategies and will conduct highly effective supervision of directors and managers.
- The Company will engage in constructive dialogue with shareholders.
Corporate Governance Reforms in Recent Years
The Company has adopted a corporate governance framework as a Company with an Audit & Supervisory Committee, under which management oversight and business execution are clearly separated through the Executive Officer system. The Board of Directors provides strategic oversight, while the Audit & Supervisory Committee independently audits and supervises the execution of duties by Directors. In addition, the Group Nomination Committee and the Group Compensation Committee have been established to enhance the fairness, objectivity, and transparency of director nomination and remuneration processes.
Corporate Governance Structure
Board of Directors
The Board of Directors meets in principle once a month and convenes extraordinary meetings as necessary. The Board determines key strategic and management matters, including management plans, and oversees business execution. Directors focus on management and oversight functions, including setting strategic direction and strengthening the effectiveness of supervision.
Key items discussed by the Board of Directors and their details
- Management policy and management strategy
Business plans and budgets, quarterly business execution status, important contract conclusions, matters related to Group companies, etc. - Capital policy and shareholder returns
Dividends, disposal of Company assets, etc. - Governance and sustainability
Various committee matters, evaluation of effectiveness of the Board of Directors, etc. - Internal control and risk management
Reporting on status of internal controls and compliance system - Other
Organizational changes, personnel transfers, rule changes, general shareholders’ meetings, etc.
Board of Directors and Management Council Deliberation Time
Composition of the Board of Directors
Evaluations of the Effectiveness of the Board of Directors
To ascertain the current status of and further improve the effectiveness of the Board of Directors, each year the Company conducts a questionnaire survey of all members of the Board of Directors.
Implementation Guidelines(FY2025)
| Target | Board Members (All nine Board of Directors members and all four Audit & Supervisory Board members) |
|---|---|
| Evaluation method |
|
| Main items of the survey |
|
Results of Evaluation
Items Yielding High Scores
Based on evaluation and analysis of the survey results, we confirmed that the Board of Directors is functioning appropriately and that the effectiveness of the Board as a whole is assured. The three items yielding the highest scores were appropriate disclosure of non-financial information, confirmation of how each division is executing its business, and confirmation of the effectiveness of the whistleblower system. We recognize these as strengths of our Board of Directors. Based on the results of this evaluation, the Board of Directors will further enhance the functions of the Board and will continue striving to improve its effectiveness.
Items Yielding Lower Scores and Improvement Initiatives
| Item | Outline | Improvement initiatives |
|---|---|---|
| Relationship between human resources strategy and corporate value | Lack of alignment between human resources strategy and management strategy, and visualization of the impact on corporate value | Currently reviewing oversight of human resources strategy and reporting on this to the Board of Directors |
| Implementation of ongoing training for Board members | Enhancing training for Board members | Implementing ongoing training for Board members |
| Discussion on business portfolio with consideration for cost of capital | Promoting discussion on business portfolio in a manner conscious of cost of capital | Discussing business portfolio in a manner conscious of cost of capital |
| DX promotion | Driving DX promotion initiatives | Consistently reporting on DX promotion efforts |
| Content and quantity of materials for Board of Directors meetings | Method of sharing and managing the materials | Promotion of paperless meetings |
Number of the Board of Directors held
| Fiscal Year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Number of the Board of Directors held | 17 | 16 | 15 | 15 | 15 |
※Figures up to FY2020 are those of ASKA Pharmaceutical Co., Ltd.
Number of Members of the Board of Directors and Outside Directors
As of June 24, 2026, the Company had 53.8% outside directors.
| Fiscal Year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|
| Total number of members of the Board of Directors | 9 | 9 | 6 | 8 | 8 | 8 | 9 | 9 | 13 |
| Of which, total number of the Outside Directors | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 7 |
※Figures up to FY2020 are those of ASKA Pharmaceutical Co., Ltd.
Number and Ratio of female Board Members (Board Diversity)
As of June 24, 2026, the Company had 23.1% female directors.
| Fiscal Year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|
| Number of female Board Members | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 3 | 3 |
| Ratio of female Board Members | 0 | 0 | 0 | 12.5 | 12.5 | 12.5 | 22.2 | 33.3 | 23.1 |
※Figures up to FY2020 are those of ASKA Pharmaceutical Co., Ltd.
Management Council
Management Council meetings are held basically once a month to deliberate/make decisions on management-related issues, and to examine important issues including management policies and strategies.
Business Strategy Meeting of the Group
To ensure the appropriateness of business operations, the Company has established a supervisory department responsible for managing subsidiaries in an integrated manner. The Company also holds the Business Strategy Meeting of the Group four times a year to share information.
Audit and Supervisory Committee
The Audit and Supervisory Committee, in order to contribute to the Company's sustainable and sound management, audits the execution of duties by Directors (excluding Directors who are Audit and Supervisory Committee Members) in accordance with the Audit and Supervisory Committee Regulations and Audit and Supervisory Committee Auditing Standards. To this end, the Committee attends important meetings, including Board of Directors meetings, reviews important approval documents and other relevant materials, and hears reports on the status of business execution from Directors and executive departments. In addition, the Committee determines its opinions regarding the appointment, dismissal, and remuneration of Directors (excluding Directors who are Audit and Supervisory Committee Members).
Committees
Group Nomination Committee and Group Remuneration Committee
The Group Nomination Committee and the Group Compensation Committee serve as advisory bodies to the Board of Directors and are composed solely of Outside Directors. The committees conduct fair and transparent deliberations on matters relating to the nomination, reappointment, dismissal, and compensation of Directors, and submit recommendations to the Board of Directors.
Key items discussed by Group Nomination Committee and Group Remuneration Committee and their details
Group Nomination Committee
- Discussion on the procedures for the election of directors
- Decision on the contents of the report to the Board of Directors
Group Remuneration Committee
- Identifying issues and items to consider for remunerations for Board Members and exchanging opinions
- Discussion on the amount of remuneration for Board Members
- Decision on the contents of the report to the Board of Directors
ESG Committee
The ESG Committee has identified 11 material issues from the perspective of relevance to the Group’s business and social contribution, and it has established a Company-wide action plan and KPIs for each of them. In particular, we believe that contribution to women’s health and contribution to animal health are two material issues in which we can demonstrate our strengths and originality.
In addition, we consider climate change issues to be one of the management issues that affect our business, and we disclose information on climate change in line with TCFD recommendations.
As a company involved in life-related issues, and as a member of society and the community, the Group broadly contributes to society by promoting ESG (environmental, social, and governance) initiatives, thereby contributing to the achievement of the SDGs (sustainable development goals).
Group Compliance Promotion Committee
The Group has established a Group Compliance Promotion Committee within the Holdings to recognize and respond to risks that may have a significant impact on Group management and to promote a compliance system that ensures strict adherence to laws, regulations, and corporate ethics, and to oversee this system.
Succession Planning
The Company views succession planning as an important management issue. To ensure that the process is transparent, fair, and objective, screening of potential leadership successors is spearheaded by the Group Nomination Committee, which is chaired by an Outside Director, and of which Outside Directors make up the majority. The Group Nomination Committee determines the selection criteria for top management positions and makes recommendations based on extensive debate over a range of candidate attributes including experience, accomplishments, personality, skills and aptitude, and performance in an interview. The Group Nomination Committee also devises training for leadership candidates to ensure that the Company achieves sustained growth and fulfills its responsibility to society.
Selection Criteria for Top Management Positions
| Personality attributes |
|
|---|---|
| Skills |
|
Nomination Process
Skill Matrix
Note: The expertise and skills possessed by the members of the Board of Directors, as well as those required to achieve the Mid-Term Management Plan, are indicated.
| Name | Position | Corpo rate manage ment |
R & D Intelle ctual property |
Sales Marke ting |
Medi cine Pharm acy |
Global business |
Finance Account ing |
Legal Risk manage ment |
Sus taina bility ESG |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Members of the Board of Directors |
Takashi Yamaguchi
|
Member of the Board of Directors, Representative Director, Chairman of the Board | ● | ● | ● | |||||
Sohta Yamaguchi
|
President, Member of the Board of Directors, Representative Director | ● | ● | ● | ● | ● | ||||
Atsushi Maruo
|
Senior Managing Member of the Board of Directors, Representative Director | ● | ● | ● | ● | ● | ||||
Maiko Mori
|
Member of the Board of Directors, Executive Corporate Officer | ● | ● | ● | ||||||
Fumiyoshi Yamaguchi
|
Member of the Board of Directors, Executive Corporate Officer | ● | ● | ● | ||||||
Minoru Awabayashi
|
Member of the Board of Directors, Outside Director | ● | ● | ● | ● | ● | ||||
Yasuji Enokido
|
Member of the Board of Directors, Outside Director | ● | ● | ● | ● | ● | ||||
Kanae Karita
|
Member of the Board of Directors, Outside Director | ● | ● | ● | ||||||
Kiyoko Kato
|
Member of the Board of Directors, Outside Director | ● | ● | ● | ||||||
James C. Feliciano
|
Member of the Board of Directors, Outside Director | ● | ● | ● | ● | |||||
| Member of the Board of Directors, Audit and Supervisory Committee Member |
Kunihiro Gunji
|
Member of the Board of Directors, Audit and Supervisory Committee Member | ● | ● | ● | ● | ||||
Takao Kimura
|
Member of the Board of Directors, Outside Director, Audit and Supervisory Committee Member | ● | ● | ● | ● | |||||
Koki Yamashita
|
Member of the Board of Directors, Outside Director, Audit and Supervisory Committee Member | ● | ● | ● | ● |
Reason for selection of skills
| Skill item | Reason for selection of skills |
|---|---|
| Corporate management | Amid major changes in the business environment, we need directors with extensive knowledge, experience, and achievements in not only the medical and pharmaceutical industries but also in general corporate management to formulate and promote a medium- to long-term sustainable growth strategy for us to realize our Group’s goal of becoming a total healthcare company with a strong foundation as a specialty pharma company. |
| R&D / Intellectual property | To continue creating products that meet unmet medical needs, it is essential that we strengthen our R&D capabilities through open innovation and globalize intellectual property activities. We need directors who have strong knowledge, experience, and achievements in the fields of R&D and intellectual property to promote these activities. |
| Sales / Marketing | Amid the rapidly changing environment surrounding medical care and animal health businesses, we need directors who have strong knowledge, experience, and achievements in sales and marketing fields to continue providing patients and healthcare professionals with information on the proper use of drugs and products. |
| Medicine / Pharmacy | In order to realize the Group’s goal of becoming a total healthcare company, we need directors who have strong knowledge, experience, and achievements in the fields of medicine and pharmacy to widely contribute to human and animal health which ranges from prevention, testing, diagnosis to treatment, and prognosis management. |
| Global business | In the healthcare business, the adaptation and strategic expansion to international markets in addition to domestic markets are indispensable and we need to understand global regulations and market trends and control risk. |
| Finance / Accounting | In addition to accurate financial reporting, we need directors who have strong knowledge, experience, and achievements in the finance and accounting fields to formulate and promote a financial and capital strategy that balances ensuring a stable financial base and improving capital efficiency, and achieves appropriate shareholder returns. |
| Legal / Risk management | The establishment of an appropriate governance system is the foundation for sustainable corporate value improvement. To promote a compliance system that ensures thorough compliance with laws and corporate ethics, we need directors who have strong knowledge, experience, and achievements in legal and risk management. |
| Sustainability / ESG | With sustainability at the core of our management, the Group aims to enhance corporate value by not only maximizing our economic value but also by increasing our social value. To achieve this, we need directors who have strong knowledge, experience, and achievements in the sustainability and ESG fields. |
Attendance status of Board of Directors, Audit & Supervisory Board and other committees (FY2025)
Board of Directors (Attendance in FY2025)
| Position | Name | Gender | Attendance |
|---|---|---|---|
| Member of the Board of Directors, Representative Director, Chairman of the Board | Takashi Yamaguchi | Male | 100% (15/15) |
| President, Member of the Board of Directors, Representative Director | ◎ Sohta Yamaguchi | Male | 100% (15/15) |
| Senior Managing Member of the Board of Directors, Representative Director | Atsushi Maruo | Male | 100% (15/15) |
| Member of the Board of Directors, Executive Corporate Officer | Maiko Mori | Female | 100% (15/15) |
| Member of the Board of Directors, Executive Corporate Officer | Fumiyoshi Yamaguchi | Male | 100% (15/15) |
| Member of the Board of Directors (Outside Director) | Minoru Awabayashi | Male | 93% (14/15) |
| Member of the Board of Directors (Outside Director) | Yasuji Enokido | Male | 100% (15/15) |
| Member of the Board of Directors (Outside Director) | Kanae Karita | Female | 100% (15/15) |
| Member of the Board of Directors (Outside Director) | Kiyoko Kato | Female | 90% (10/11) |
| Audit & Supervisory Board Member | Kunihiro Gunji | Male | 100% (15/15) |
| Audit & Supervisory Board Member | Kazuhiro Chiku | Male | 100% (11/11) |
| Outside Audit & Supervisory Board Member | Takao Kimura | Male | 100% (15/15) |
| Outside Audit & Supervisory Board Member | Koki Yamashita | Male | 100% (11/11) |
◎: Chairman The attendance records of Ms. Kiyoko Kato, Mr. Kazuhiro Chiku, and Mr. Koiki Yamashita cover only the meetings of the Board of Directors held after their appointment on June 24, 2025. * FY2025: 9 members (including 4 external members)
Audit & Supervisory Board (Attendance in FY2025)
| Position | Name | Attendance |
|---|---|---|
| Audit & Supervisory Board Member | ◎ Kunihiro Gunji | 100% (15/15) |
| Audit & Supervisory Board Member | Kazuhiro Chiku | 100% (11/11) |
| Outside Audit & Supervisory Board Member | Takao Kimura | 100% (15/15) |
| Outside Audit & Supervisory Board Member | Koki Yamashita | 100% (11/11) |
◎: Chairman * The attendance records of Mr. Kazuhiro Chiku and Mr. Koki Yamashita cover only the meetings of Audit & Supervisory Board held after their appointment on June 24, 2025. * FY2025: 4 members (including 2 external members)
Group Nomination Committee (Attendance in FY2025)
| Position | Name | Attendance |
|---|---|---|
| Member of the Board of Directors (Outside Director) | ◎ Minoru Awabayashi | 100% (6/6) |
| Member of the Board of Directors (Outside Director) | Yasuji Enokido | 100% (6/6) |
| Member of the Board of Directors (Outside Director) | Kanae Karita | 100% (4/4) |
◎: Chairman * FY2025: 3 members (all external)
Group Remuneration Committee (Attendance in FY2025)
| Position | Name | Attendance |
|---|---|---|
| Member of the Board of Directors (Outside Director) | ◎ Minoru Awabayashi | 100% (5/5) |
| Member of the Board of Directors (Outside Director) | Yasuji Enokido | 100% (5/5) |
| Member of the Board of Directors (Outside Director) | Kanae Karita | 100% (3/3) |
◎: Chairman The attendance records of Ms. Karita Kanae cover only Group Remuneration Committee held after their appointment on June 24, 2025. * FY2025: 3 members (all external)
ESG Committee (Attendance in FY2025)
| Position | Name | Attendance |
|---|---|---|
| President, Member of the Board of Directors, Representative Director | Sohta Yamaguchi | 100% (2/2) |
| Senior Managing Member of the Board of Directors, Representative Director | ◎Atsushi Maruo | 100% (2/2) |
| Member of the Board of Directors, Executive Corporate Officer | Fumiyoshi Yamaguchi | 100% (2/2) |
◎: Chairman * Only board members are listed.
Group Compliance Promotion Committee (Attendance in FY2025)
| Position | Name | Attendance |
|---|---|---|
| Senior Managing Member of the Board of Directors, Representative Director | ◎Atsushi Maruo | 100% (2/2) |
| Member of the Board of Directors, Executive Corporate Officer | Maiko Mori | 100% (2/2) |
| Member of the Board of Directors, Executive Corporate Officer | Fumiyoshi Yamaguchi | 100% (2/2) |
◎: Chairman * Only board members are listed.
Cross-Shareholdings
Cross-Shareholdings Policy
The Company will cross-shareholdings that it judges will contribute to the maintenance and improvement of the Group's corporate value from the perspective of business expansion and the maintenance and strengthening of business relationships. However, the Board of Directors will examine and verify the corporate performance and financial conditions of each shareholder, management indicators of profitability and growth potential, and the comparison between the benefits of holding the shares and the cost of capital, and will reduce the number of shares held if the significance of holding such shares is not necessarily sufficient, based on the results of dialogue with the shareholder. The Board of Directors will examine and review the comparison of the cost of capital and other factors.
Criteria for the Exercise of Voting Rights in relation to Cross-Shareholdings
Cross-shareholdings shall be voted in accordance with the following policy.
- The Company shall make a comprehensive judgment as to whether or not the shares will contribute to the maintenance and improvement of the corporate value of the Group by examining the corporate performance, financial condition, and stance on returning profits to shareholders, while taking into account the business relationship with the shareholder.
- Exercise voting rights for proposals that are deemed problematic in terms of their efforts to enhance corporate value and shareholder returns by taking into consideration the results of dialogue with the counterparties and other factors, and by considering how such proposals will contribute to improving such problems.
Countermeasures for Takeovers
The Company has not introduced any countermeasures for takeovers.
Tax Policy
- The Group will comply with all tax-related laws and regulations pertaining to Group operations.
- The Group will ensure tax transparency and proper tax payment.
Human Rights
Human Rights Policy
As a signatory to the United Nations Global Compact (hereinafter referred to as "UN Global Compact"), ASKA Pharmaceutical Holdings Group (hereinafter referred to as "Group") agrees with the Ten Principles in the four areas (human rights, labor, environment, and anti-corruption) of the UN Global Compact and will implement them under the responsibility of top management itself.
Scope of Application
This policy applies to all officers and employees of the Group. The Group will require all domestic and overseas stakeholders involved in its business activities, including those in the supply chain, to have a similar understanding of the policy.
Prohibition of discrimination
The Group prohibits discrimination and harassment of any kind on the basis of race, nationality, ethnicity, social status, gender, disability, health status, age, skin color, religion, creed or ideology, sexual orientation or gender identity.
Respect for freedom of association and the right to collective bargaining
In accordance with applicable laws and regulations, the Group will respect the freedom of association and the right to collective bargaining of its employees, guarantee the rights of its employees, and maintain and promote sound and good labor-management relations without discrimination.
Improvement of working environment and wages
The Group will comply with laws and regulations, manage working hours appropriately, grant days off, vacations, etc., and strive to maintain a workplace environment that allows the Group's employees to work in a safe and secure condition. Moreover, the Group will comply with legal requirements regarding statutory benefits and deductions, overtime, etc. in each region, and ensure that the amount of wages exceeds the statutory minimum wage standards.
Prohibition of forced labor
The Group does not tolerate any form of forced labor, human trafficking, and child labor.
Whistle-blower system
The Group has established the ASKA Pharmaceutical Holdings Compliance Consultation Hotline as an internal whistleblowing channel to ensure that employees’ concerns regarding unfair discrimination and harassment in the workplace, including sexual harassment and power harassment, are reflected in the implementation of compliance practices. In addition, the Group has established an Audit & Supervisory Committee Hotline, operated by a Full-time Audit & Supervisory Committee Member of ASKA Pharmaceutical Holdings, as a dedicated channel through which compliance-related matters involving Group officers can be reported or discussed. Reports may be submitted anonymously, and all reported matters are addressed appropriately. In accordance with the spirit of Japan’s Whistleblower Protection Act, the Group operates this system not only to protect whistleblowers, but also to ensure that compliance-related matters are collected, investigated, and remedied in a timely and appropriate manner.
Human rights education
In order to realize a company and society free of all forms of discrimination, the Group provides training on the importance of respect for human rights and compliance, and promotes the creation of a workplace where each employee can maximize his or her abilities while protecting the dignity of others.
Human rights due diligence
As a system to reflect the voices of employees regarding unfair discrimination and harassment in the workplace, sexual harassment, and power harassment in compliance practice, the Group has established a whistle-blower office, the “ASKA Pharmaceutical Holdings’ compliance consulting desk,” and a new contact point for consultation and reporting of compliance-related matters involving its officers, “Audit & Supervisory Board member consulting desk.” It is staffed by ASKA Pharmaceutical Holdings’ Audit & Supervisory Board members.
Human rights promotion system
The Company promotes company-wide ESG initiatives under the ESG Promotion Meeting. The Committee of Managers for ESG Promotion is responsible for formulating goals and action plans for each department. Specifically, the Company is continuously addressing key ESG issues, including responses to the TCFD and TNFD frameworks, as well as matters related to human rights and the supply chain.
Respect for Human Rights
The Company's Charter of Corporate Behavior stipulates that the Company shall "respect human rights and comply with all laws, regulations, codes of conduct, and the spirit of such laws and regulations, whether in Japan or overseas, and act with the highest ethical standards and social conscience.” The CSR guiding principles state that the Company respects the human rights of all people affected by its corporate activities, respects the diversity of its employees, and fosters a safe and comfortable corporate culture. To realize a discrimination-free society and business in all forms, the Company provides training on the importance of respect for human rights and compliance and promotes the creation of a workplace where each employee can maximize his or her potential while protecting the dignity of all employees.
Favorable Labor-Management Relations
The Company also focuses on its relationship with the labor union, and by holding and responding to many labor-management discussions on various issues related to working conditions and the working environment, as well as various issues related to work styles in support of the next generation, the Company guarantees employee rights and maintains and promotes sound and healthy labor-management relations.
Prevention of Harassment in the Workplace
The Company believes that unjust discrimination, harassment, sexual harassment, and power harassment in the workplace are important issues related to human rights violations in the sense that they violate the right to work in a comfortable work environment and are extremely despicable behaviors. To prevent and eliminate such harassment, the Company takes necessary care in employment management and conducts employee training. In particular, the Company ensures that executives and managers acquire correct knowledge and raise their awareness of harassment prevention through the use of guidebooks and more specific examples in their training on harassment.
Dialogue with Shareholders
In order to realize sustainable growth and medium- to long-term improvement of corporate value, the Company considers it essential to obtain appropriate evaluation and trust from shareholders and investors, and shall engage in dialogue with shareholders and investors in a rational and continuous manner. In addition, through IR activities, the Company shall strive to enhance shareholders' and investors' understanding of the Company's management strategies, etc. by appropriately disclosing and explaining the Company's management strategies, business performance, financial conditions, capital policies, etc. to shareholders and investors.
The Company shall appoint a director in charge from among its directors to promote constructive dialogue with shareholders and investors, including IR activities. The Director in Charge shall be responsible for overall dialogue with shareholders and investors, and shall strive to realize constructive dialogue.
In addition to the director in charge, the actual dialogue will be conducted by a designated person based on the shareholder/investor's wishes and the main concerns of the meeting, but the department in charge will assist the interlocutor in cooperation with the respective departments in order to provide accurate information.
In order to make the dialogue more constructive and meaningful, we will continue to work on appropriate information dissemination and enhancement of disclosure content and means of dialogue and provide feedback on the content of the dialogue to the Board of Directors through the director in charge, as necessary.
In addition, when engaging in dialogue, the Company shall also strive to appropriately manage insider information by, for example, not selectively disclosing undisclosed material information to specific persons in accordance with the "Public Relations Regulations" separately established.